Literature DB >> 29506889

Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism.

Kuo-How Huang1, Chih-Chin Yu2, Ya-Hui Hu3, Chin-Chen Chang4, Chieh-Kai Chan5, Shih-Cheng Liao6, Yao-Chou Tsai7, Shih-Chieh Jeff Chueh8, Vin-Cent Wu9, Yen-Hung Lin10.   

Abstract

BACKGROUND/
PURPOSE: Even with the increasing recognition of primary aldosteronism (PA) as a cause of refractory hypertension and an issue of public health, the consensus of its optimal surgical or medical treatment in Taiwan has not been reached. Our objective was to develop a clinical practice guideline that is feasible for real-world management of PA patients in Taiwan.
METHODS: The Taiwan Society of Aldosteronism (TSA) Task Force recognized the above-mentioned issues and reached this Taiwan PA consensus at its inaugural meeting, in order to provide updated information of internationally acceptable standards, and also to incorporate our local disease characteristics and constraints into PA management.
RESULTS: In patients with lateralized PA, including aldosterone producing adenoma (APA), laparoscopic adrenalectomy is the 'gold standard' of treatment. Mini-laparoscopic and laparoendoscopic single-site approaches are feasible only in highly experienced surgeons. Patients with bilateral adrenal hyperplasia or those not suitable for surgery should be treated by mineralocorticoid receptor antagonists. The outcome data of PA patient management from the literature, especially from PA patients in Taiwan, are reviewed. Mental health screening is helpful in early detection and management of psychopathology among PA patients.
CONCLUSION: We hope this consensus will provide a guideline to help medical professionals to manage PA patients in Taiwan to achieve a better quality of care.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Guideline; Primary aldosteronism; TAIPAI

Mesh:

Substances:

Year:  2018        PMID: 29506889     DOI: 10.1016/j.jfma.2018.01.006

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  9 in total

1.  2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.

Authors:  Tzung-Dau Wang; Chern-En Chiang; Ting-Hsing Chao; Hao-Min Cheng; Yen-Wen Wu; Yih-Jer Wu; Yen-Hung Lin; Michael Yu-Chih Chen; Kwo-Chang Ueng; Wei-Ting Chang; Ying-Hsiang Lee; Yu-Chen Wang; Pao-Hsien Chu; Tzu-Fan Chao; Hsien-Li Kao; Charles Jia-Yin Hou; Tsung-Hsien Lin
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

Review 2.  Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far?

Authors:  Huai Heng Loh; Norlela Sukor
Journal:  J Hum Hypertens       Date:  2019-12-10       Impact factor: 3.012

3.  NP-59 Adrenal Scintigraphy as an Imaging Biomarker to Predict KCNJ5 Mutation in Primary Aldosteronism Patients.

Authors:  Ching-Chu Lu; Ruoh-Fang Yen; Kang-Yung Peng; Jei-Yie Huang; Kwan-Dun Wu; Jeff S Chueh; Wan-Yu Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-28       Impact factor: 5.555

4.  The Quality of Clinical Practice Guidelines and Consensuses on the Management of Primary Aldosteronism: A Critical Appraisal.

Authors:  Zhe Meng; Liang Zhou; Zhe Dai; Chang Xu; Guofeng Qian; Mou Peng; Yuchun Zhu; Joey S W Kwong; Xinghuan Wang
Journal:  Front Med (Lausanne)       Date:  2020-05-05

Review 5.  Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Authors:  Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu
Journal:  Front Cardiovasc Med       Date:  2022-02-02

6.  Recurrence of Primary Aldosteronism 10 Years After Left Adrenalectomy for Aldosterone-Producing Adenoma: A Case Report.

Authors:  Linghui Kong; Jin Zhang; Lei Dong; Jianzhong Xu; Ping-Jin Gao; Ji-Guang Wang; Limin Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-24       Impact factor: 5.555

7.  New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies.

Authors:  Cheng-Hsuan Tsai; Ya-Li Chen; Chien-Ting Pan; Yen-Tin Lin; Po-Chin Lee; Yu-Wei Chiu; Che-Wei Liao; Zheng-Wei Chen; Chin-Chen Chang; Yi-Yao Chang; Chi-Sheng Hung; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

8.  Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis.

Authors:  Wei-Chieh Huang; Ying-Ying Chen; Yen-Hung Lin; Jeff S Chueh
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

9.  Evaluation of Abdominal Computed Tomography Scans for Differentiating the Discrepancies in Abdominal Adipose Tissue Between Two Major Subtypes of Primary Aldosteronism.

Authors:  Kuan-Ming Chen; Bo-Ching Lee; Po-Ting Chen; Kao-Lang Liu; Kuan-Heng Lin; Chin-Chen Chang; Tung-Hsin Wu; Jia-Sheng Hong; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-16       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.